Medical Pharmacology: Chapter: 25 — Pulmonary Pharmacology -- Module: 3 — Methylxanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

Chapter: 25 — Pulmonary Pharmacology — Module: 3 — Methylxanthines, Leukotriene Modifiers, and Mast Cell Stabilizers
Tier: CC (Concept Check)

1. A 58-year-old man with severe COPD (chronic obstructive pulmonary disease) is started on oral theophylline as an add-on bronchodilator. Which of the following best describes the primary cellular mechanism by which theophylline produces bronchodilation at therapeutic serum concentrations?

A) Competitive antagonism of adenosine A2B receptors on mast cells, preventing histamine release and reducing bronchoconstriction
B) Inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) in airway smooth muscle, raising intracellular cAMP and activating protein kinase A to reduce contractility
C) Direct activation of beta-2 adrenergic receptors on airway smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP
D) Blockade of muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-driven bronchoconstriction
E) Inhibition of leukotriene synthesis by blocking 5-lipoxygenase, reducing cysteinyl leukotriene-mediated airway constriction

ANSWER: B

Rationale:

Theophylline's primary bronchodilatory mechanism at therapeutic concentrations is inhibition of PDE3 (phosphodiesterase 3) and PDE4 (phosphodiesterase 4) in airway smooth muscle and inflammatory cells. These isoforms are responsible for degrading cyclic AMP (cAMP); PDE inhibition raises intracellular cAMP, activates protein kinase A (PKA), phosphorylates myosin light chain kinase, and reduces airway smooth muscle contractility, producing bronchodilation. PDE4 inhibition in inflammatory cells also provides a modest anti-inflammatory effect.

Option A: Option A is incorrect because adenosine A2B antagonism is a secondary mechanism contributing to reduced mast cell degranulation, not the primary bronchodilatory pathway.
Option C: Option C is incorrect because theophylline does not activate beta-2 adrenergic receptors; beta-2 agonists stimulate adenylyl cyclase directly, while theophylline prevents cAMP breakdown — a mechanistically distinct action.
Option D: Option D is incorrect because muscarinic M3 blockade is the mechanism of anticholinergic bronchodilators such as ipratropium and tiotropium, not methylxanthines.
Option E: Option E is incorrect because 5-lipoxygenase inhibition is the mechanism of zileuton, a leukotriene modifier with a completely different pharmacological target than theophylline.

2. A pulmonology fellow is reviewing theophylline dosing with a medical student during rounds. The student asks what serum concentration range is considered therapeutic for theophylline in the management of asthma and COPD. Which of the following correctly identifies the established therapeutic range and the rationale for targeting the lower portion of that range in many patients?

A) 5–10 mcg/mL; this range produces maximal bronchodilation while avoiding any risk of adverse effects
B) 20–30 mcg/mL; serum concentrations must reach this level before meaningful phosphodiesterase inhibition occurs in airway smooth muscle
C) 1–5 mcg/mL; theophylline's narrow therapeutic index requires very low serum concentrations to avoid toxicity in all patients
D) 10–20 mcg/mL; bronchodilatory benefit increases across this range, but many clinicians target 8–12 mcg/mL to reduce toxicity risk while accepting modest reduction in peak efficacy
E) 25–35 mcg/mL; the older therapeutic range was overly conservative, and revised guidelines recommend higher target concentrations for maximum efficacy

ANSWER: D

Rationale:

The established theophylline therapeutic serum concentration range is 10–20 mcg/mL. Bronchodilatory benefit increases progressively across this range, but significant toxicity becomes probable above 20 mcg/mL and life-threatening toxicity — including seizures and ventricular arrhythmias — is common above 40 mcg/mL. Many clinicians now target the lower portion of the range (8–12 mcg/mL) to reduce toxicity risk, particularly for COPD maintenance dosing where sustained bronchodilation rather than maximum acute effect is the goal.

Option A: Option A is incorrect because concentrations of 5–10 mcg/mL fall below the lower boundary of the established therapeutic range and do not reliably produce optimal bronchodilation, though some clinicians accept the lower sub-range of 8–12 mcg/mL for safety.
Option B: Option B is incorrect because 20–30 mcg/mL exceeds the upper boundary of the therapeutic window and represents concentrations at which adverse effects — gastrointestinal, cardiac, and neurological — are clinically significant.
Option C: Option C is incorrect because 1–5 mcg/mL is subtherapeutic; meaningful PDE inhibition and bronchodilation require concentrations substantially higher than this range.
Option E: Option E is incorrect because no guideline body recommends a target range of 25–35 mcg/mL; this range is firmly within the toxic zone and is not supported by any evidence or current clinical practice.

3. A 44-year-old woman with status asthmaticus unresponsive to nebulized albuterol and IV (intravenous) methylprednisolone is being considered for IV aminophylline. The senior resident reminds the team to account for the theophylline content of aminophylline when calculating the dose. Which of the following correctly describes the relationship between aminophylline and theophylline?

A) Aminophylline is the ethylenediamine salt of theophylline used for IV administration, containing 79–86% theophylline by weight; doses are calculated in aminophylline but serum monitoring uses theophylline concentrations
B) Aminophylline is a prodrug that is enzymatically converted to theophylline in the liver; its theophylline content is fixed at exactly 50% by weight across all formulations
C) Aminophylline and theophylline are chemically identical compounds; the names are used interchangeably in clinical practice without any dose conversion required
D) Aminophylline contains approximately 10–15% theophylline by weight; most of the molecular mass is composed of the ethylenediamine carrier, which is pharmacologically inactive
E) Aminophylline is an active metabolite of theophylline generated during hepatic CYP1A2 (cytochrome P450 1A2) metabolism; it is used intravenously because theophylline itself cannot be dissolved in aqueous solution

ANSWER: A

Rationale:

Aminophylline is the ethylenediamine salt of theophylline and is the formulation used for intravenous administration because it has greater water solubility than theophylline alone. It contains 79–86% theophylline by weight. Clinically, this means that doses are prescribed and calculated in milligrams of aminophylline, but serum therapeutic drug monitoring is performed using theophylline concentrations, since the ethylenediamine component is pharmacologically inactive. Loading doses must account for any theophylline concentration already present to avoid inadvertent overdose.

Option B: Option B is incorrect because aminophylline is not a prodrug requiring enzymatic activation; it releases theophylline by simple dissociation in aqueous solution, and the theophylline content is approximately 79–86%, not 50%.
Option C: Option C is incorrect because aminophylline and theophylline are chemically distinct compounds with different molecular weights; dose interchangeability without conversion would result in underdosing or overdosing.
Option D: Option D is incorrect because the theophylline content is 79–86%, not 10–15%; the ethylenediamine moiety accounts for only a small fraction of the molecular mass.
Option E: Option E is incorrect because aminophylline is not a metabolite of theophylline; it is a salt formulation of theophylline, and the pharmacokinetic relationship is the reverse — theophylline is the active species released from aminophylline, not the other way around.

4. A 67-year-old man with COPD (chronic obstructive pulmonary disease) has been stable on oral sustained-release theophylline for two years. His physician increases the dose by 20% to improve symptom control. Three days later he presents with nausea, vomiting, and palpitations; his theophylline level is 34 mcg/mL. Which pharmacokinetic property of theophylline best explains why a modest dose increase produced a disproportionately large rise in serum concentration?

A) Theophylline undergoes extensive first-pass hepatic metabolism that becomes saturated at higher doses, dramatically increasing its oral bioavailability
B) Theophylline is highly protein-bound, and small dose increases displace it from albumin binding sites, markedly increasing the free drug fraction
C) As theophylline concentrations approach and exceed the therapeutic range, hepatic metabolism becomes saturated and elimination shifts toward zero-order (Michaelis-Menten) kinetics, causing disproportionate accumulation with small dose increments
D) Theophylline undergoes autoinduction of CYP1A2, which initially increases clearance but then abruptly collapses after several days, causing serum levels to surge
E) Theophylline is renally eliminated by active tubular secretion that becomes saturated at higher serum concentrations, reducing its renal clearance and causing drug accumulation

ANSWER: C

Rationale:

Theophylline's elimination follows first-order kinetics at low concentrations but shifts toward Michaelis-Menten (zero-order, saturable) kinetics as concentrations approach and exceed the therapeutic range. When hepatic CYP1A2-mediated metabolism becomes saturated, clearance is no longer proportional to concentration; a proportionally small dose increase produces a disproportionately large rise in serum concentration. This is the pharmacokinetic basis for the clinical observation that theophylline toxicity can appear suddenly after a small dose adjustment in a previously stable patient.

Option A: Option A is incorrect because theophylline does not undergo significant first-pass metabolism; it has high oral bioavailability (approximately 90–100%) without saturable first-pass extraction being a clinically relevant factor in toxicity.
Option B: Option B is incorrect because while theophylline is approximately 40% protein-bound, displacement from albumin at higher doses is not a clinically significant mechanism for the disproportionate accumulation seen with dose escalation; it does not explain the sharp nonlinear relationship.
Option D: Option D is incorrect because theophylline does not cause autoinduction of CYP1A2; autoinduction is a property of drugs such as carbamazepine, not methylxanthines.
Option E: Option E is incorrect because theophylline is eliminated primarily by hepatic metabolism (more than 90%), not renal tubular secretion; renal saturation does not drive theophylline accumulation in clinical dosing.

5. A 55-year-old man with COPD (chronic obstructive pulmonary disease) smokes one pack of cigarettes per day and is maintained on oral theophylline 600 mg daily, achieving a stable serum concentration of 14 mcg/mL. Which of the following correctly explains why this patient requires a higher theophylline dose than a non-smoking patient of similar weight and renal function?

A) Cigarette smoking increases theophylline renal clearance by inducing tubular secretion transporters, requiring higher doses to maintain therapeutic serum concentrations
B) Nicotine directly competes with theophylline for protein binding on albumin, reducing theophylline's free fraction and necessitating higher total doses
C) Carbon monoxide from cigarette smoke inhibits theophylline absorption in the small intestine, reducing oral bioavailability and requiring dose compensation
D) Tobacco smoke induces adenosine A1 receptors in airway smooth muscle, requiring higher theophylline concentrations to achieve equivalent receptor blockade
E) Polycyclic aromatic hydrocarbons in tobacco smoke potently induce hepatic CYP1A2 (cytochrome P450 1A2), the primary enzyme responsible for theophylline metabolism, substantially increasing theophylline clearance and requiring 50–60% higher doses in active smokers

ANSWER: E

Rationale:

Cigarette smoking is the most quantitatively significant CYP1A2 inducer in clinical practice. Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke — not nicotine itself — induce CYP1A2 expression through aryl hydrocarbon receptor (AhR) signaling. Since CYP1A2 is the primary enzyme responsible for theophylline hepatic metabolism, smokers have substantially increased theophylline clearance and require doses approximately 50–60% higher than non-smokers to achieve equivalent serum concentrations. Critically, if this patient stops smoking, CYP1A2 induction will wane over 1–2 weeks and theophylline clearance will fall, causing serum levels to rise toward toxicity at the previously stable dose.

Option A: Option A is incorrect because theophylline is eliminated primarily by hepatic metabolism (more than 90%), not renal tubular secretion; smoking does not induce renal drug transporters in a manner that significantly alters theophylline clearance.
Option B: Option B is incorrect because nicotine does not compete with theophylline for albumin binding; protein displacement is not the pharmacokinetic basis for the smoking-theophylline dose difference.
Option C: Option C is incorrect because cigarette smoke components do not meaningfully reduce oral theophylline bioavailability; theophylline is well absorbed regardless of smoking status, and altered absorption is not the mechanism.
Option D: Option D is incorrect because smoking does not upregulate adenosine receptors; adenosine receptor antagonism is a secondary theophylline mechanism, and the dose difference reflects altered drug clearance, not receptor sensitivity.

6. A 70-year-old woman with COPD (chronic obstructive pulmonary disease) maintained on sustained-release theophylline develops a community-acquired pneumonia and is started on ciprofloxacin by her primary care physician. Four days later she presents to the emergency department with nausea, tremor, and a heart rate of 118 beats per minute. Her theophylline level is 27 mcg/mL (baseline 13 mcg/mL). Which of the following best explains this drug interaction?

A) Ciprofloxacin displaces theophylline from albumin binding, increasing the free fraction of theophylline and producing toxicity despite a modest rise in total serum concentration
B) Ciprofloxacin inhibits CYP1A2 (cytochrome P450 1A2), the primary enzyme responsible for theophylline hepatic metabolism, reducing theophylline clearance by approximately 30–50% and causing serum concentrations to rise to toxic levels
C) Ciprofloxacin induces CYP3A4 (cytochrome P450 3A4), shifting theophylline metabolism toward a pathway that produces a toxic oxidative metabolite rather than inactive products
D) Ciprofloxacin competitively inhibits active renal tubular secretion of theophylline through shared organic cation transporter pathways, reducing urinary elimination
E) Ciprofloxacin blocks theophylline's adenosine receptor antagonism by competitively binding to A1 and A2 receptors, paradoxically increasing adenosine-mediated cardiac stimulation

ANSWER: B

Rationale:

Ciprofloxacin is the most clinically important CYP1A2 inhibitor in routine practice for patients receiving theophylline. Fluoroquinolone antibiotics, particularly ciprofloxacin, reduce theophylline clearance by approximately 30–50% through CYP1A2 inhibition, producing a corresponding rise in serum theophylline concentrations that can precipitate toxicity within days of starting the antibiotic. In this patient, the baseline theophylline level of 13 mcg/mL nearly doubled to 27 mcg/mL after ciprofloxacin was added — a magnitude entirely consistent with CYP1A2 inhibition. When ciprofloxacin is required in a theophylline-treated patient, theophylline dose reduction and close serum level monitoring are mandatory.

Option A: Option A is incorrect because protein displacement is not a clinically significant mechanism for this interaction; theophylline is only approximately 40% protein-bound, and displacement does not account for the doubling of total serum concentration observed.
Option C: Option C is incorrect because ciprofloxacin inhibits rather than induces CYP enzymes, and it does not generate a toxic theophylline metabolite via CYP3A4 induction.
Option D: Option D is incorrect because theophylline is eliminated primarily by hepatic CYP1A2 metabolism (more than 90%); renal tubular secretion of theophylline is not a significant elimination pathway and ciprofloxacin does not share organic cation transporter competition with theophylline to a clinically meaningful degree.
Option E: Option E is incorrect because ciprofloxacin has no pharmacological activity at adenosine receptors; its theophylline interaction is entirely pharmacokinetic, not pharmacodynamic.

7. A 62-year-old man taking oral theophylline for COPD (chronic obstructive pulmonary disease) calls his physician reporting nausea and vomiting that began yesterday. His most recent theophylline level three weeks ago was 16 mcg/mL. Which of the following best characterizes the clinical significance and mechanism of gastrointestinal toxicity in theophylline excess?

A) Nausea and vomiting in theophylline toxicity are caused solely by direct mucosal irritation in the stomach and do not reflect systemic theophylline toxicity; they resolve with antacid therapy without dose adjustment
B) Gastrointestinal symptoms are a late manifestation of theophylline toxicity that appear only after cardiac arrhythmias and seizures have already developed, making them a poor early warning sign
C) Theophylline-induced nausea is mediated exclusively by adenosine A2B receptor activation in the gut wall and resolves spontaneously once tolerance develops within 48 hours regardless of serum concentration
D) Gastrointestinal toxicity — nausea, vomiting, and abdominal cramping — is the earliest and most common manifestation of theophylline excess, appearing at serum concentrations of 15–25 mcg/mL and serving as a clinical warning that levels are rising toward the dangerous range
E) Gastrointestinal symptoms in theophylline toxicity are entirely predictable and reliable indicators of toxicity threshold in all patient populations, including those with chronic theophylline exposure

ANSWER: D

Rationale:

Gastrointestinal toxicity — nausea, vomiting, and abdominal cramping — is the earliest and most common manifestation of theophylline excess, typically appearing at serum concentrations in the range of 15–25 mcg/mL. The mechanism involves both local gastric mucosal irritation from theophylline contact and central emetic stimulation via adenosine receptor antagonism in the CNS (central nervous system). GI symptoms frequently serve as the clinical warning sign that serum levels are rising toward the dangerous range, and their new appearance in a patient on stable theophylline therapy warrants prompt level measurement.

Option A: Option A is incorrect because GI symptoms in theophylline excess are not limited to local mucosal irritation; central adenosine receptor antagonism contributes substantially, and the symptoms are a systemic toxicity signal requiring dose assessment, not antacid therapy alone.
Option B: Option B is incorrect because gastrointestinal symptoms are an early manifestation of theophylline toxicity, preceding rather than following cardiac and neurological toxicity; they are actually valuable precisely because they can alert the clinician before life-threatening complications develop.
Option C: Option C is incorrect because GI symptoms are mediated by both local mucosal and central mechanisms, not exclusively by A2B receptor activation; furthermore, GI tolerance in chronic toxicity partially blunts — but does not eliminate — this warning, and symptoms do not reliably resolve within 48 hours without addressing the underlying elevated concentration.
Option E: Option E is incorrect because GI symptoms are specifically unreliable as a toxicity threshold marker in patients with chronic theophylline toxicity, in whom partial tolerance to GI effects may develop; conversely, in acute overdose, life-threatening effects can appear alongside or shortly after GI symptoms.

8. A 74-year-old man with COPD (chronic obstructive pulmonary disease) is brought to the emergency department with a theophylline level of 38 mcg/mL. His ECG (electrocardiogram) shows multifocal atrial tachycardia at 138 beats per minute and his serum potassium is 3.0 mEq/L. Which of the following best explains the dual cardiac and electrolyte findings in this patient?

A) Theophylline-induced cardiac toxicity is driven by adenosine A1 receptor antagonism at the SA (sinoatrial) and AV (atrioventricular) nodes combined with theophylline-stimulated catecholamine release; hypokalemia occurs because the resulting beta-2 adrenergic stimulation drives potassium into cells, lowering the threshold for ventricular arrhythmias
B) Theophylline directly inhibits the Na-K-ATPase pump in cardiac myocytes, producing hypokalemia by preventing potassium reabsorption and causing cardiac toxicity by increasing intracellular sodium
C) Theophylline blocks cardiac beta-1 adrenergic receptors at toxic concentrations, producing compensatory tachycardia through baroreceptor reflex activation and reducing renal potassium reabsorption
D) Theophylline toxicity causes SIADH (syndrome of inappropriate antidiuretic hormone secretion), leading to dilutional hypokalemia and reflex sympathetic tachycardia in response to electrolyte disturbance
E) Cardiac arrhythmias in theophylline toxicity are caused by direct PDE3 inhibition in cardiac pacemaker cells, which increases intracellular cAMP beyond the physiological range and destabilizes the action potential

ANSWER: A

Rationale:

Theophylline-induced cardiac toxicity involves two complementary mechanisms. First, adenosine A1 receptor antagonism at the SA (sinoatrial) node removes adenosine's normal inhibitory brake on pacemaker automaticity, increasing heart rate; A1 antagonism at the AV node also impairs normal conduction regulation. Second, theophylline stimulates epinephrine release from the adrenal medulla, augmenting sympathetic tone further. The resulting surge in catecholamine activity drives potassium into skeletal muscle cells via beta-2 adrenergic receptor-mediated Na-K-ATPase activation, producing hypokalemia. Hypokalemia compounds arrhythmia risk by lowering the ventricular arrhythmia threshold. Multifocal atrial tachycardia is particularly characteristic of theophylline toxicity, especially in the setting of underlying lung disease.

Option B: Option B is incorrect because theophylline does not inhibit Na-K-ATPase; that is the mechanism of cardiac glycoside toxicity (digoxin), not methylxanthine toxicity; theophylline-induced hypokalemia is driven by beta-2-mediated cellular potassium shift, not pump inhibition.
Option C: Option C is incorrect because theophylline does not block beta-1 adrenergic receptors; it is an adenosine receptor antagonist and PDE inhibitor; beta-1 blockade would slow rather than accelerate the heart rate.
Option D: Option D is incorrect because theophylline toxicity does not cause SIADH; the hypokalemia in theophylline toxicity is a transcellular shift driven by catecholamine-stimulated beta-2 receptor activity, not a dilutional process.
Option E: Option E is incorrect because while PDE3 inhibition contributes to theophylline's bronchodilatory effect, the predominant mechanism of cardiac arrhythmia at toxic concentrations is adenosine receptor antagonism combined with catecholamine excess, not isolated PDE3-driven cAMP elevation in pacemaker cells.

9. A 59-year-old man with a theophylline level of 52 mcg/mL develops a generalized tonic-clonic seizure in the emergency department. Which of the following best characterizes the neurological toxicity of theophylline at this concentration and its clinical management implications?

A) Theophylline-induced seizures are reliably controlled by standard doses of IV lorazepam and rarely require additional anticonvulsant agents, because benzodiazepines are highly effective at reversing adenosine receptor-mediated seizure activity
B) Theophylline-induced seizures are caused by direct GABA-A (gamma-aminobutyric acid type A) receptor blockade and are specifically treated with high-dose phenobarbital, which restores GABA-mediated inhibition
C) Theophylline-induced seizures are frequently refractory to standard anticonvulsant therapy, may be the first clinical manifestation of toxicity in some patients, and carry high mortality; hemodialysis is indicated for severe toxicity to reduce theophylline concentrations rapidly
D) Theophylline-induced seizures occur only after cardiac arrhythmias have developed and serve as a reliable clinical marker that hemodialysis is not yet necessary
E) Theophylline-induced seizures at serum concentrations above 50 mcg/mL are managed with oral activated charcoal alone, which interrupts enterohepatic recirculation and reduces serum concentrations within 30 minutes

ANSWER: C

Rationale:

Theophylline-induced seizures are among the most dangerous complications of methylxanthine toxicity. They are frequently refractory to standard benzodiazepine and phenytoin anticonvulsant therapy, may be the first dramatic clinical manifestation of toxicity in some patients (particularly those with acute rather than chronic overdose), and carry a high mortality when they occur. The mechanism involves adenosine A1 receptor antagonism in the CNS (central nervous system) — adenosine normally exerts an inhibitory, anticonvulsant influence in the brain — compounded by theophylline-stimulated catecholamine release. Hemodialysis is highly effective at removing theophylline and is indicated for severe toxicity with serum concentrations above 90 mcg/mL in acute overdose, or above 40–60 mcg/mL in chronic toxicity, or at any concentration in a patient with life-threatening arrhythmia or refractory seizures. This patient's level of 52 mcg/mL with active seizures meets the threshold for dialysis consideration.

Option A: Option A is incorrect because theophylline-induced seizures are specifically notable for being refractory to standard benzodiazepine therapy; while benzodiazepines are the first-line empirical choice, they frequently fail to control theophylline seizures, which is a key clinical distinction from most other drug-induced or metabolic seizures.
Option B: Option B is incorrect because theophylline does not directly block GABA-A receptors; its CNS excitatory mechanism is adenosine A1 antagonism and catecholamine release; phenobarbital may be used as an adjunct but is not the specific mechanistic antidote.
Option D: Option D is incorrect because theophylline seizures can occur as the first clinical presentation of toxicity, preceding or coinciding with — not following — cardiac arrhythmias, particularly in acute overdose; and the presence of seizures at any concentration is an indication to expedite hemodialysis, not defer it.
Option E: Option E is incorrect because oral activated charcoal is used for gastrointestinal decontamination and multi-dose charcoal can enhance elimination by interrupting enterohepatic recirculation, but it does not reduce serum concentrations within 30 minutes and is not the management strategy for a patient already seizing with a level of 52 mcg/mL.

10. A 61-year-old man with COPD (chronic obstructive pulmonary disease) has smoked one pack per day for 35 years and has been stable on theophylline 700 mg daily with a serum level of 15 mcg/mL. He enrolls in a smoking cessation program and successfully quits cigarettes. Two weeks later he presents with nausea, tremor, and palpitations; his theophylline level is now 28 mcg/mL. Which of the following correctly explains this clinical scenario?

A) Nicotine withdrawal increases gastrointestinal motility and theophylline absorption, raising serum concentrations independent of any change in hepatic metabolism
B) Smoking cessation triggers upregulation of adenosine receptors in airway smooth muscle, increasing theophylline's pharmacodynamic potency and producing toxicity at previously tolerated concentrations
C) Abrupt nicotine withdrawal stimulates adrenal catecholamine release, which inhibits CYP1A2 directly and reduces theophylline clearance within 24 hours of quitting
D) Smoking cessation reduces theophylline protein binding by removing tobacco-derived competitive displacing agents from albumin binding sites, raising the free theophylline fraction
E) Smoking cessation causes CYP1A2 induction — previously maintained by polycyclic aromatic hydrocarbons in tobacco smoke — to wane over 1–2 weeks, reducing theophylline clearance and causing serum concentrations to rise to toxic levels at the previously stable dose

ANSWER: E

Rationale:

Polycyclic aromatic hydrocarbons (PAHs) in cigarette smoke are potent CYP1A2 inducers. When a patient who has been maintained on a theophylline dose calibrated to smoker-level clearance quits smoking, the PAH-driven CYP1A2 induction diminishes progressively over 1–2 weeks as the enzyme returns to baseline expression levels. Theophylline clearance falls correspondingly, and serum concentrations rise at the unchanged dose. This is a recurring and preventable cause of theophylline toxicity: clinicians managing COPD patients on theophylline must anticipate this pharmacokinetic consequence of smoking cessation and proactively reduce the theophylline dose by approximately 30–50% when cessation occurs, followed by serum level monitoring.

Option A: Option A is incorrect because nicotine withdrawal does not meaningfully increase gastrointestinal theophylline absorption; theophylline oral bioavailability is already high (approximately 90–100%) in smokers and non-smokers alike, and altered absorption does not explain a near-doubling of serum concentration.
Option B: Option B is incorrect because smoking cessation does not upregulate adenosine receptors; the toxicity in this scenario is a pharmacokinetic consequence of reduced drug clearance, not a pharmacodynamic change in receptor sensitivity.
Option C: Option C is incorrect because nicotine withdrawal does not directly inhibit CYP1A2 through catecholamine release; the enzyme change is driven by the loss of PAH-mediated induction and occurs over days to weeks, not within 24 hours.
Option D: Option D is incorrect because tobacco components do not competitively displace theophylline from albumin; protein binding changes are not the mechanism for the observed concentration rise after smoking cessation.

11. A second-year resident is reviewing the leukotriene biosynthesis pathway before a pulmonology clinic. Which of the following correctly describes the sequence of enzymatic steps by which arachidonic acid is converted to the cysteinyl leukotrienes in mast cells and eosinophils?

A) Arachidonic acid is converted by COX-2 (cyclooxygenase-2) to prostaglandin G2, which is then reduced by peroxidase to the unstable LTA4 epoxide, the branch point for leukotriene B4 and cysteinyl leukotriene synthesis
B) Phospholipase A2 releases arachidonic acid from membrane phospholipids; 5-LOX (5-lipoxygenase) acting with the FLAP (5-LOX-activating protein) cofactor converts it to 5-HPETE (5-hydroperoxyeicosatetraenoic acid) and then to LTA4; LTA4 is either hydrolyzed to LTB4 or conjugated with glutathione by LTC4 synthase to form LTC4
C) Arachidonic acid is directly conjugated with cysteine by LTC4 synthase without an intermediate epoxide, forming LTC4 in a single enzymatic step that bypasses the 5-HPETE and LTA4 intermediates entirely
D) The leukotriene pathway begins with thromboxane A2 synthesis by COX-1 (cyclooxygenase-1); thromboxane A2 is then converted by 5-LOX to LTB4 in neutrophils, bypassing the cysteinyl leukotriene branch entirely in mast cells
E) Arachidonic acid is first converted to LTD4 by a constitutively active leukotrieneD4 synthase in the cytoplasm; LTD4 is then sequentially cleaved to LTC4 and LTE4 by gamma-glutamyl transpeptidase and dipeptidase

ANSWER: B

Rationale:

The leukotriene biosynthesis pathway begins when phospholipase A2 (PLA2) releases arachidonic acid (AA) from cell membrane phospholipids in response to inflammatory stimuli. 5-lipoxygenase (5-LOX), acting in concert with the 5-LOX-activating protein (FLAP) anchored to the nuclear membrane, then converts AA first to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and then to the unstable epoxide leukotriene A4 (LTA4). LTA4 is a critical branch point: it is either hydrolyzed by LTA4 hydrolase to LTB4, or conjugated with glutathione by LTC4 synthase to form LTC4, the first cysteinyl leukotriene. LTC4 is then sequentially cleaved extracellularly to LTD4 and LTE4 by gamma-glutamyl transpeptidase and dipeptidase, respectively.

Option A: Option A is incorrect because COX-2 generates prostaglandins and thromboxanes, not leukotrienes; LTA4 is not a product of the COX pathway, and prostaglandin G2 is not a precursor to any leukotriene.
Option C: Option C is incorrect because LTC4 synthesis requires the intermediate LTA4 epoxide; arachidonic acid cannot be directly conjugated to glutathione without first passing through the 5-HPETE and LTA4 intermediates — the LTA4 backbone is essential for the conjugation reaction.
Option D: Option D is incorrect because thromboxane A2 is a COX-1 product with no relationship to 5-LOX or leukotriene synthesis; the two pathways — COX and 5-LOX — diverge at arachidonic acid and are enzymatically independent.
Option E: Option E is incorrect because the cysteinyl leukotriene pathway runs LTC4 → LTD4 → LTE4 (sequential cleavage by extracellular peptidases), not in reverse; LTD4 is not the primary synthesized product but is derived from LTC4 by gamma-glutamyl transpeptidase cleavage.

12. Which of the following correctly identifies the most potent endogenous CysLT1 (cysteinyl leukotriene receptor 1) agonist and accurately describes the intracellular signaling cascade that produces airway smooth muscle contraction upon CysLT1 activation?

A) LTD4 (leukotriene D4) is the most potent CysLT1 agonist; CysLT1 couples through Gq protein to phospholipase C, generating IP3 (inositol trisphosphate) and DAG (diacylglycerol); IP3 triggers calcium release from the sarcoplasmic reticulum, producing airway smooth muscle contraction
B) LTB4 (leukotriene B4) is the most potent CysLT1 agonist; it signals through Gs protein to adenylyl cyclase, raising intracellular cAMP (cyclic adenosine monophosphate) and activating protein kinase A, which phosphorylates myosin and produces bronchoconstriction
C) LTE4 (leukotriene E4) is the most potent CysLT1 agonist because it is the terminal, most stable cysteinyl leukotriene; it signals through Gi protein to reduce adenylyl cyclase activity, lowering cAMP and allowing unopposed smooth muscle contraction
D) LTC4 (leukotriene C4) is the most potent CysLT1 agonist; CysLT1 couples through Gq protein but signals exclusively through the DAG (diacylglycerol) branch of PLC, activating protein kinase C without any calcium release component
E) LTD4 is the most potent CysLT1 agonist, but CysLT1 signals through beta-arrestin-mediated receptor internalization rather than G protein coupling, making the contraction response slower in onset and resistant to receptor-level pharmacological blockade

ANSWER: A

Rationale:

LTD4 (leukotriene D4) is the most potent endogenous CysLT1 agonist, followed by LTC4 and LTE4 in decreasing order of potency. Upon binding LTD4, CysLT1 couples through Gq protein to phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds its receptor on the sarcoplasmic reticulum membrane and triggers calcium release into the cytoplasm, producing airway smooth muscle (ASM) contraction. CysLTs are approximately 1000-fold more potent than histamine as bronchoconstrictors on a molar basis.

Option B: Option B is incorrect because LTB4 is not a CysLT1 agonist at all; LTB4 signals through BLT1 (leukotriene B4 receptor 1) and BLT2 receptors on neutrophils and acts as a potent chemotactic agent, not a direct bronchoconstrictor; the signaling cascade described — Gs/cAMP/PKA — describes beta-2 adrenergic bronchodilation, not bronchoconstriction.
Option C: Option C is incorrect because LTE4 is the least potent cysteinyl leukotriene at CysLT1, not the most potent; while it is the most stable and excreted cysteinyl leukotriene, its binding affinity at CysLT1 is lower than LTD4; additionally, the signaling mechanism described — Gi/reduced cAMP — does not represent CysLT1 signaling.
Option D: Option D is incorrect because CysLT1 Gq signaling generates both IP3 and DAG as simultaneous products of PLC activity; IP3-triggered calcium release is a central and essential component of the bronchoconstrictor response, not an absent branch.
Option E: Option E is incorrect because CysLT1 is a classical G protein-coupled receptor (GPCR) that signals primarily through Gq to produce rapid calcium-dependent contraction; beta-arrestin internalization is a regulatory mechanism for some GPCRs but is not the primary signaling mode of CysLT1 or the reason LTRAs are effective pharmacological blockers.

13. A pharmacology teaching session covers the relative potency of bronchoconstrictor mediators. Which of the following correctly characterizes the bronchoconstrictor potency of cysteinyl leukotrienes relative to histamine, and identifies an additional airway effect of CysLT1 activation beyond smooth muscle contraction?

A) Cysteinyl leukotrienes are approximately equipotent with histamine as bronchoconstrictors on a molar basis, but their effect is more prolonged because CysLT1 has a slower dissociation rate from bronchial smooth muscle receptors
B) Histamine is approximately 500-fold more potent than cysteinyl leukotrienes as a bronchoconstrictor on a molar basis; cysteinyl leukotrienes primarily cause mucosal edema and mucus secretion rather than direct smooth muscle contraction
C) Cysteinyl leukotrienes are approximately 10-fold more potent than histamine as bronchoconstrictors; their principal additional airway effect is stimulation of mast cell histamine release through CysLT2 receptor activation on mast cell surfaces
D) Cysteinyl leukotrienes are approximately 1000-fold more potent than histamine as bronchoconstrictors on a molar basis; in addition to bronchoconstriction, CysLT1 activation drives airway edema, goblet cell mucus secretion, eosinophil adhesion and survival, and subepithelial fibrosis through TGF-beta induction
E) Cysteinyl leukotrienes are approximately 1000-fold more potent than histamine but produce exclusively transient bronchoconstriction without any effect on airway inflammation, mucus, or airway remodeling

ANSWER: D

Rationale:

Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are approximately 1000-fold more potent than histamine as bronchoconstrictors on a molar basis, and their bronchoconstrictor effect is prolonged and partially resistant to beta-2 agonist-mediated reversal — a clinically significant distinction that partly explains the incomplete response of some asthma attacks to SABA (short-acting beta-2 agonist) monotherapy. Beyond bronchoconstriction, CysLT1 activation produces a spectrum of additional airway effects: increased vascular permeability causing airway edema, stimulation of goblet cell mucus secretion, enhanced eosinophil adhesion and survival in the airway mucosa, and promotion of subepithelial fibrosis through TGF-beta (transforming growth factor-beta) induction. These non-bronchoconstrictor effects contribute to the airway remodeling seen in chronic asthma.

Option A: Option A is incorrect because cysteinyl leukotrienes are not equipotent with histamine; they are approximately 1000-fold more potent on a molar basis, and the statement about CysLT1 dissociation rate accounting for prolonged effect does not accurately describe the known mechanism.
Option B: Option B is incorrect because histamine is the less potent bronchoconstrictor, not the more potent; the characterization that cysteinyl leukotrienes primarily cause edema and mucus without direct smooth muscle contraction is also wrong — CysLT1 activation via Gq/IP3/calcium is the direct mechanism of ASM (airway smooth muscle) contraction.
Option C: Option C is incorrect because cysteinyl leukotrienes are approximately 1000-fold more potent than histamine, not 10-fold; and cysteinyl leukotrienes do not stimulate histamine release through CysLT2 receptors — CysLT2 is expressed primarily in cardiac tissue and macrophages and is not a primary mast cell activation receptor for this pathway.
Option E: Option E is incorrect because cysteinyl leukotrienes have well-established effects beyond bronchoconstriction, including promotion of airway edema, mucus secretion, eosinophilic inflammation, and subepithelial fibrosis; characterizing their effect as exclusively transient bronchoconstriction contradicts both the basic science and the clinical rationale for LTRA use in asthma.

14. A 28-year-old woman with mild persistent asthma and seasonal allergic rhinitis is being considered for montelukast. Which of the following correctly describes montelukast's mechanism of action, approved indications, and dosing schedule?

A) Montelukast is a non-selective leukotriene receptor antagonist that blocks both CysLT1 and CysLT2 receptors; it is dosed twice daily with food to maximize absorption and is approved exclusively for asthma prophylaxis without any role in exercise-induced bronchoconstriction
B) Montelukast is a selective 5-LOX (5-lipoxygenase) inhibitor that reduces leukotriene synthesis; it is approved for asthma, allergic rhinitis, and AERD (aspirin-exacerbated respiratory disease) and requires liver function monitoring due to hepatotoxicity risk
C) Montelukast is a selective competitive CysLT1 (cysteinyl leukotriene receptor 1) antagonist administered once daily in the evening (10 mg in adults); its approved indications include asthma prophylaxis, exercise-induced bronchoconstriction (EIB), seasonal and perennial allergic rhinitis, and AERD management
D) Montelukast is a selective CysLT1 antagonist that requires morning dosing to align with peak airway hyperresponsiveness; it is approved for asthma and allergic rhinitis but is contraindicated in patients with concurrent aspirin sensitivity
E) Montelukast is a prodrug activated by CYP3A4 (cytochrome P450 3A4) to an active CysLT1-blocking metabolite; once-daily dosing is appropriate because the metabolite has a half-life exceeding 48 hours in all patient populations

ANSWER: C

Rationale:

Montelukast (Singulair) is a selective, competitive CysLT1 antagonist that blocks LTC4, LTD4, and LTE4 binding at the CysLT1 receptor on airway smooth muscle and inflammatory cells. It is administered once daily in the evening (10 mg tablets in adults; 5 mg chewable tablets in children aged 6–14; 4 mg granules in children aged 2–5). The evening dosing convention reflects the circadian pattern of leukotriene production and the nocturnal worsening of asthma symptoms. Its approved indications include chronic asthma prophylaxis, exercise-induced bronchoconstriction (EIB), seasonal and perennial allergic rhinitis, and management of AERD as part of aspirin desensitization protocol support.

Option A: Option A is incorrect because montelukast is a selective CysLT1 antagonist, not a non-selective CysLT1/CysLT2 blocker — available LTRAs do not meaningfully block CysLT2; the twice-daily dosing and food requirement describe zafirlukast, not montelukast; and montelukast is approved for EIB, not just asthma prophylaxis.
Option B: Option B is incorrect because montelukast is a CysLT1 receptor antagonist, not a 5-LOX inhibitor; 5-LOX inhibition is the mechanism of zileuton, which does require liver function monitoring; montelukast does not require routine LFT monitoring.
Option D: Option D is incorrect because montelukast is conventionally dosed in the evening, not the morning, to align with nocturnal leukotriene production patterns; and montelukast is specifically indicated and effective in AERD management, not contraindicated in aspirin-sensitive patients.
Option E: Option E is incorrect because montelukast is not a prodrug; it is pharmacologically active as administered; the once-daily dosing reflects the approximately 3–6 hour half-life of the parent compound with sustained receptor occupancy, not a 48-hour metabolite half-life.

15. A 34-year-old man with mild intermittent asthma and seasonal allergic rhinitis asks his physician about starting montelukast. The physician wishes to counsel him accurately regarding the FDA (Food and Drug Administration) boxed warning associated with this drug. Which of the following best describes the content of the montelukast boxed warning and the appropriate prescribing guidance it implies?

A) The montelukast boxed warning concerns QTc interval prolongation leading to potentially fatal ventricular arrhythmias; ECG (electrocardiogram) monitoring is required before initiating therapy and periodically thereafter in all patients
B) The montelukast boxed warning concerns hepatocellular injury; monthly liver function tests are required for the first year of therapy and the drug is contraindicated in all patients with any degree of baseline hepatic abnormality
C) The montelukast boxed warning concerns irreversible bronchoconstriction paradox in patients with aspirin sensitivity; it is contraindicated in all AERD (aspirin-exacerbated respiratory disease) patients and should not be used within six months of aspirin challenge
D) The montelukast boxed warning concerns Churg-Strauss syndrome-like systemic vasculitis in patients undergoing oral corticosteroid tapering; it is contraindicated in patients receiving any systemic corticosteroid therapy
E) The montelukast boxed warning, issued by the FDA in March 2020, concerns serious neuropsychiatric events including agitation, depression, suicidal ideation, hallucinations, and tremor; for mild asthma and allergic rhinitis, other therapies should be considered first, and patients must be counseled to discontinue and contact their prescriber if neuropsychiatric symptoms develop

ANSWER: E

Rationale:

The FDA issued a boxed warning for montelukast in March 2020 regarding serious neuropsychiatric events across all age groups, including agitation, aggression, hallucinations, dream abnormalities, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (suicidality), and tremor. The proposed mechanism involves montelukast or its metabolites crossing the blood-brain barrier (BBB) and blocking CysLT1 receptors in the CNS (central nervous system), where these receptors appear to play a role in neuroinflammatory signaling. The prescribing guidance requires that for patients with mild asthma or allergic rhinitis — where effective alternatives exist — the neuropsychiatric risk must be carefully weighed against the benefit, and other therapies should be tried first. Montelukast remains appropriate for patients with more severe disease or co-morbid allergic rhinitis-asthma phenotype where it is clinically justified, but informed counseling and documentation are mandatory.

Option A: Option A is incorrect because QTc prolongation and ventricular arrhythmia risk are not associated with montelukast and are not the subject of its boxed warning; QTc concerns are associated with other drug classes such as certain antipsychotics, antibiotics, and antihistamines, not CysLT1 antagonists.
Option B: Option B is incorrect because hepatocellular injury and liver function monitoring requirements are associated with zileuton (a 5-LOX inhibitor), not montelukast; montelukast does not carry a liver toxicity warning requiring routine LFT monitoring.
Option C: Option C is incorrect because montelukast is not contraindicated in AERD — it is actually specifically indicated and effective in AERD management because it targets the CysLT1 receptor that is activated by the leukotriene surge provoked by COX-1 inhibition.
Option D: Option D is incorrect because the Churg-Strauss syndrome-like vasculitis association is linked to zafirlukast, not montelukast, and it appears to represent unmasking of pre-existing eosinophilic granulomatosis with polyangiitis during steroid tapering rather than a direct drug effect; this is not the content of the montelukast boxed warning.

16. A 52-year-old woman with moderate asthma and atrial fibrillation maintained on warfarin is switched from montelukast to zafirlukast by her pulmonologist. Two weeks later her INR (international normalized ratio) has risen from 2.4 to 4.1 without any change in her warfarin dose. Which of the following best explains this drug interaction and identifies the additional pharmacokinetic feature of zafirlukast that distinguishes it from montelukast?

A) Zafirlukast is metabolized by CYP2D6 (cytochrome P450 2D6) and inhibits CYP1A2 at clinical concentrations, increasing warfarin levels by reducing its 1A2-mediated ring oxidation; unlike montelukast, zafirlukast must be taken with a high-fat meal to achieve adequate absorption
B) Zafirlukast is metabolized by CYP2C9 (cytochrome P450 2C9) and inhibits both CYP2C9 and CYP3A4 at clinical concentrations, increasing plasma concentrations of warfarin (a CYP2C9 substrate) and necessitating INR monitoring when co-administered; unlike montelukast, zafirlukast must be taken on an empty stomach as food reduces its bioavailability by approximately 40%
C) Zafirlukast inhibits CYP2C9 and CYP3A4, but the warfarin interaction is pharmacodynamic rather than pharmacokinetic — zafirlukast directly inhibits vitamin K epoxide reductase, reducing vitamin K recycling and augmenting warfarin's anticoagulant effect independently of drug levels
D) Zafirlukast is metabolized by CYP3A4 exclusively and inhibits CYP2C19 at clinical concentrations; the warfarin interaction occurs because warfarin is a CYP2C19 substrate; zafirlukast has no food effect and is bioequivalent whether taken fasting or with a meal
E) Zafirlukast is metabolized by CYP2C9 and causes the warfarin interaction by displacing warfarin from albumin binding sites, raising the free warfarin fraction; its absorption is reduced by approximately 40% when taken with food, identical to the food effect seen with montelukast

ANSWER: B

Rationale:

Zafirlukast is metabolized primarily by CYP2C9 (rather than CYP3A4 and CYP2C8 as with montelukast) and inhibits both CYP2C9 and CYP3A4 at clinical concentrations. Because S-warfarin — the more pharmacologically active enantiomer — is a CYP2C9 substrate, zafirlukast inhibition of CYP2C9 reduces warfarin clearance and raises warfarin plasma concentrations, producing a clinically significant increase in INR that requires monitoring whenever zafirlukast is added to stable warfarin therapy. Zafirlukast must be taken on an empty stomach because food (particularly a high-fat meal) reduces its oral bioavailability by approximately 40%, a clinically important difference from montelukast, which has no significant food effect. The patient's INR increase from 2.4 to 4.1 without any warfarin dose change is the expected consequence of this interaction.

Option A: Option A is incorrect because zafirlukast is primarily metabolized by CYP2C9, not CYP2D6, and inhibits CYP2C9 and CYP3A4, not CYP1A2; additionally, zafirlukast must be taken without food (on an empty stomach), not with a high-fat meal.
Option C: Option C is incorrect because the zafirlukast-warfarin interaction is pharmacokinetic (CYP2C9 inhibition raising warfarin plasma concentrations), not pharmacodynamic; zafirlukast does not directly inhibit vitamin K epoxide reductase — that is the mechanism of warfarin itself.
Option D: Option D is incorrect because zafirlukast is metabolized primarily by CYP2C9 (not exclusively CYP3A4) and inhibits CYP2C9 and CYP3A4 (not CYP2C19); warfarin is not primarily a CYP2C19 substrate; and zafirlukast does have a significant food effect (40% reduced bioavailability when taken with food).
Option E: Option E is incorrect because protein displacement from albumin is not the mechanism of the zafirlukast-warfarin interaction; the interaction is driven by CYP2C9 inhibition and the resulting pharmacokinetic increase in warfarin plasma concentrations; the food effect information is correct but the mechanism attribution is wrong, making the entire option incorrect.

17. A pulmonologist is considering zileuton as an add-on controller agent for a 38-year-old man with moderate persistent asthma poorly controlled on ICS (inhaled corticosteroids) and a LABA (long-acting beta-2 agonist). Which of the following correctly distinguishes zileuton from the CysLT1 (cysteinyl leukotriene receptor 1) antagonists montelukast and zafirlukast?

A) Zileuton selectively blocks CysLT1 receptors with greater affinity than montelukast but has no effect on LTB4 (leukotriene B4)-mediated neutrophilic inflammation; it requires monitoring of serum creatinine due to nephrotoxicity risk
B) Zileuton is a competitive CysLT1 and CysLT2 dual receptor antagonist that suppresses both cysteinyl leukotriene and LTB4 signaling by blocking the shared receptor complex; it has no hepatic metabolism and requires no liver function monitoring
C) Zileuton inhibits LTC4 synthase selectively, preventing only cysteinyl leukotriene synthesis without affecting LTB4; it has an identical safety profile to montelukast and requires the same neuropsychiatric boxed warning monitoring
D) Zileuton inhibits 5-LOX (5-lipoxygenase) directly, reducing synthesis of all leukotrienes including both LTB4 and the cysteinyl leukotrienes; this upstream mechanism provides broader leukotriene suppression than CysLT1 antagonists; zileuton requires periodic liver function test monitoring due to hepatocellular injury risk
E) Zileuton acts upstream of 5-LOX by inhibiting phospholipase A2, preventing arachidonic acid release from membrane phospholipids and thereby suppressing both leukotriene and prostaglandin synthesis; it requires platelet count monitoring due to thrombocytopenia risk

ANSWER: D

Rationale:

Zileuton (Zyflo, Zyflo CR) occupies a mechanistically distinct position among leukotriene modifiers: rather than blocking CysLT1 receptors like montelukast and zafirlukast, it inhibits 5-lipoxygenase (5-LOX) directly. Because 5-LOX catalyzes the first committed step in leukotriene synthesis, zileuton reduces synthesis of all leukotrienes — including both LTB4 (leukotriene B4, a potent neutrophil chemoattractant acting through BLT1 receptors) and the cysteinyl leukotrienes (LTC4, LTD4, LTE4). This upstream mechanism provides broader leukotriene suppression than CysLT1-selective antagonists, which block only the receptor without affecting LTB4-mediated neutrophilic inflammation. Zileuton requires monitoring of liver function tests (LFTs) at baseline and periodically thereafter — monthly for the first three months, every 2–3 months for the remainder of the first year — because it causes hepatocellular injury in a small percentage of patients; it is contraindicated when liver enzymes exceed 3 times the upper limit of normal (ULN).

Option A: Option A is incorrect because zileuton is not a CysLT1 receptor antagonist; it is a 5-LOX enzyme inhibitor that suppresses leukotriene synthesis; zileuton's toxicity concern is hepatotoxicity requiring LFT monitoring, not nephrotoxicity; and it does affect LTB4-mediated inflammation by reducing LTB4 synthesis.
Option B: Option B is incorrect because zileuton is not a receptor antagonist of any kind; it is an enzyme inhibitor acting at 5-LOX; the description of a "shared receptor complex" for CysLT and LTB4 is pharmacologically inaccurate since these ligands act at entirely different receptor families.
Option C: Option C is incorrect because zileuton does not selectively inhibit LTC4 synthase; it inhibits 5-LOX, which is upstream of the LTA4 branch point and therefore reduces both LTB4 and all cysteinyl leukotriene synthesis; zileuton does not carry the neuropsychiatric boxed warning associated with montelukast.
Option E: Option E is incorrect because zileuton does not inhibit phospholipase A2; its target is 5-LOX, which acts downstream of arachidonic acid release; phospholipase A2 inhibition is a theoretical mechanism of some corticosteroids (via lipocortin/annexin induction), not of zileuton; zileuton does not carry a thrombocytopenia warning.

18. A 45-year-old man with refractory moderate-severe asthma is maintained on oral theophylline at a dose achieving a serum concentration of 12 mcg/mL. His pulmonologist adds zileuton for additional leukotriene suppression. Which of the following best describes the expected pharmacokinetic interaction and the required dose adjustment?

A) Zileuton inhibits CYP1A2 (cytochrome P450 1A2), the primary enzyme responsible for theophylline metabolism; co-administration can double theophylline serum concentrations within days, requiring theophylline dose reduction by approximately 50% and careful serum level monitoring
B) Zileuton induces CYP1A2, increasing theophylline clearance and reducing serum concentrations; theophylline dose should be increased by approximately 50% when zileuton is initiated to maintain therapeutic levels
C) Zileuton competes with theophylline for albumin binding, displacing theophylline and raising its free fraction; clinical monitoring of free theophylline levels (rather than total levels) is required, but no dose adjustment is necessary
D) Zileuton inhibits CYP3A4 exclusively and increases theophylline concentrations by reducing its minor CYP3A4-mediated metabolic pathway; dose reduction of approximately 15% is recommended and total serum monitoring is sufficient
E) Zileuton and theophylline share the same CYP1A2 metabolic pathway, resulting in competitive inhibition; theophylline levels fall initially as zileuton preferentially occupies the enzyme, but return to baseline after 2–3 weeks of co-administration as enzyme induction normalizes clearance

ANSWER: A

Rationale:

Zileuton is metabolized by CYP1A2 (cytochrome P450 1A2), CYP2C9, and CYP3A4, and it inhibits CYP1A2 at clinical concentrations. Because CYP1A2 is the primary enzyme responsible for theophylline hepatic metabolism, zileuton's CYP1A2 inhibition can double theophylline serum concentrations within days of co-administration. This interaction is clinically critical: when zileuton is added to theophylline therapy, theophylline dose should be reduced by approximately 50% and serum theophylline levels must be monitored carefully to avoid toxicity. The magnitude of this interaction — a potential doubling of theophylline concentrations — makes it one of the most clinically important drug interactions in pulmonary pharmacology.

Option B: Option B is incorrect because zileuton inhibits CYP1A2, not induces it; CYP1A2 induction would reduce theophylline levels (as seen with cigarette smoking and rifampin), while inhibition raises them; dose should be decreased, not increased.
Option C: Option C is incorrect because the zileuton-theophylline interaction is not protein displacement; it is a pharmacokinetic drug interaction at the level of CYP1A2-mediated hepatic metabolism; free theophylline level monitoring is not the appropriate response, and dose adjustment is required.
Option D: Option D is incorrect because the clinically important zileuton-theophylline interaction occurs through CYP1A2 inhibition, not CYP3A4 inhibition alone; the degree of theophylline concentration increase is approximately 100% (doubling), not 15%; and monitoring total serum theophylline with a 15% dose reduction would be inadequate to prevent toxicity.
Option E: Option E is incorrect because zileuton inhibits CYP1A2 rather than competing for it as a co-substrate; theophylline levels rise, not fall, upon zileuton addition; there is no autoinduction mechanism that normalizes clearance after 2–3 weeks — the inhibitory effect persists throughout co-administration.

19. A pediatric pulmonologist is discussing mast cell stabilizers with a student who asks why cromolyn sodium is rarely used for asthma today compared to its widespread use in prior decades. Which of the following correctly describes cromolyn's mechanism of action, its fundamental limitation as a therapeutic agent, and the reason for its diminished clinical role?

A) Cromolyn is a mast cell stabilizer with potent bronchodilatory activity at therapeutic doses; its diminished use reflects the discovery that its mechanism — cysteinyl leukotriene receptor blockade — is duplicated by newer, more convenient oral LTRAs (leukotriene receptor antagonists) such as montelukast
B) Cromolyn inhibits 5-LOX (5-lipoxygenase) in mast cells, reducing cysteinyl leukotriene synthesis; its diminished use reflects hepatotoxicity concerns identified in post-marketing surveillance that resulted in an FDA black box warning in 2002
C) Cromolyn is a mast cell stabilizer that prevents mediator release by blocking chloride channels on the mast cell surface, inhibiting the calcium influx required for granule exocytosis; it is strictly prophylactic with no bronchodilatory activity, and its diminished use reflects the demonstrated superiority of ICS (inhaled corticosteroids) in reducing exacerbations, airway hyperresponsiveness, and providing better symptom control
D) Cromolyn reversibly inhibits IgE binding to mast cell surface FcεRI (high-affinity IgE receptor), preventing allergen-driven degranulation; its diminished use reflects the availability of omalizumab, a monoclonal antibody that achieves the same mechanism with monthly subcutaneous dosing
E) Cromolyn stabilizes mast cells by activating beta-2 adrenergic receptors on the mast cell surface, raising intracellular cAMP and inhibiting degranulation; its diminished use reflects the recognition that inhaled beta-2 agonists achieve the same mast cell stabilization more efficiently

ANSWER: C

Rationale:

Cromolyn sodium (Intal) is a mast cell stabilizer whose mechanism, not fully established, appears to involve blockade of chloride channels on the mast cell surface, preventing the calcium influx and membrane depolarization required for exocytosis of secretory granules containing histamine and other preformed mediators. Cromolyn also inhibits sensory nerve activation in the airway. Crucially, it has no bronchodilatory activity whatsoever — it is strictly prophylactic and must be administered before allergen exposure or exercise to be effective; it provides no benefit once bronchoconstriction is established. Its clinical role has contracted dramatically because multiple controlled trials demonstrated that low-dose ICS provides superior asthma control, greater reduction in airway hyperresponsiveness, and better exacerbation prevention than cromolyn or nedocromil at equivalent dosing frequency. Current GINA (Global Initiative for Asthma) guidelines do not include mast cell stabilizers as preferred or alternative controller agents at any step for adults.

Option A: Option A is incorrect because cromolyn has no meaningful bronchodilatory activity and does not act through CysLT1 receptor blockade; its mechanism (mast cell stabilization via chloride channel blockade) is entirely distinct from LTRA pharmacology; the parallel to LTRAs is mechanistically incorrect.
Option B: Option B is incorrect because cromolyn does not inhibit 5-LOX; it prevents mediator release from mast cells without affecting leukotriene synthesis enzymes; and cromolyn has no hepatotoxicity warning or FDA black box warning — it has an excellent safety profile with virtually no systemic adverse effects.
Option D: Option D is incorrect because cromolyn does not inhibit IgE binding to FcεRI (high-affinity immunoglobulin E receptor); that is the mechanism of omalizumab, a biologic agent; cromolyn acts downstream of IgE receptor crosslinking by blocking the cellular activation event.
Option E: Option E is incorrect because cromolyn does not activate beta-2 adrenergic receptors; it is not a sympathomimetic and has no mechanism overlap with beta-2 agonists; the statement attributes the pharmacology of a completely different drug class to cromolyn.

20. A 42-year-old woman with a history of nasal polyposis and asthma develops acute bronchoconstriction, nasal congestion, and flushing within 45 minutes of taking ibuprofen for a headache. She is diagnosed with AERD (aspirin-exacerbated respiratory disease). Which of the following correctly describes the pathophysiological mechanism responsible for her reaction?

A) Ibuprofen triggers IgE-mediated mast cell degranulation through a cross-reactive antigenic epitope shared among all NSAIDs (non-steroidal anti-inflammatory drugs), releasing histamine and tryptase and producing a Type I hypersensitivity reaction identical to drug allergy
B) Ibuprofen competitively blocks CysLT1 receptors at low doses but produces paradoxical CysLT1 agonism at therapeutic doses, directly stimulating airway smooth muscle contraction and mast cell degranulation through receptor superactivation
C) Ibuprofen inhibits COX-2 (cyclooxygenase-2) selectively, reducing prostaglandin I2 (prostacyclin) production in airway endothelium, which normally suppresses mast cell responsiveness; loss of prostacyclin allows unopposed mast cell histamine release
D) Ibuprofen directly activates 5-LOX (5-lipoxygenase) through allosteric binding to the enzyme's regulatory FLAP (5-LOX-activating protein) domain, causing constitutive leukotriene synthesis independent of arachidonic acid availability
E) Ibuprofen inhibits COX-1 (cyclooxygenase-1), reducing PGE2 (prostaglandin E2) synthesis; in AERD patients, PGE2 normally restrains mast cell and eosinophil 5-LOX activity through EP2 receptors; loss of this restraint diverts arachidonic acid into the 5-LOX pathway, producing a surge in cysteinyl leukotriene synthesis that drives bronchoconstriction, nasal congestion, and urticaria within 30–180 minutes

ANSWER: E

Rationale:

AERD (aspirin-exacerbated respiratory disease), also known as Samter's triad or aspirin-sensitive asthma, is driven by a pharmacological rather than IgE-mediated mechanism. In AERD patients, there is constitutive overproduction of cysteinyl leukotrienes by airway mast cells and eosinophils, in part because of reduced baseline prostaglandin E2 (PGE2) synthesis. PGE2 normally exerts an anti-inflammatory restraining influence on mast cell and eosinophil 5-LOX activity through EP2 (prostaglandin E2 receptor subtype 2) receptors. When COX-1 is inhibited by ibuprofen or any other COX-1-inhibiting NSAID, PGE2 synthesis falls abruptly. The loss of EP2-mediated restraint allows arachidonic acid (AA) to be shunted preferentially into the 5-LOX pathway, causing a surge in cysteinyl leukotriene synthesis. The resulting CysLT surge at CysLT1 receptors drives bronchoconstriction, nasal congestion, flushing, and urticaria within 30–180 minutes. This pharmacological mechanism explains why all COX-1-inhibiting NSAIDs share cross-reactivity in AERD.

Option A: Option A is incorrect because AERD reactions are not IgE-mediated; there is no specific antigenic epitope shared among NSAIDs that would explain cross-reactivity; the mechanism is entirely pharmacological (COX-1 inhibition), not immunological, which is why skin testing and specific IgE assays are not useful diagnostically.
Option B: Option B is incorrect because ibuprofen is not a CysLT1 receptor antagonist at any dose and does not produce paradoxical CysLT1 agonism; it has no direct activity at CysLT1 receptors and its effects on the leukotriene pathway are entirely indirect through COX-1 inhibition and consequent AA shunting.
Option C: Option C is incorrect because ibuprofen inhibits both COX-1 and COX-2 (it is a non-selective NSAID, not a selective COX-2 inhibitor); the AERD mechanism operates through COX-1 inhibition reducing PGE2, not through prostacyclin loss; prostacyclin (PGI2) reduction at airway endothelium is not the primary mechanism described for AERD pathophysiology.
Option D: Option D is incorrect because ibuprofen does not directly activate or allosterically bind 5-LOX; it has no direct enzymatic activity at 5-LOX or FLAP; its role in 5-LOX pathway activation is entirely indirect, through removing PGE2-mediated inhibitory signaling on mast cell and eosinophil 5-LOX.

21. A patient with confirmed AERD (aspirin-exacerbated respiratory disease) asks her allergist which pain relievers and anti-inflammatory agents she can safely use. Which of the following correctly identifies the safe analgesic and anti-inflammatory options for a patient with AERD and explains the basis for cross-reactivity among unsafe agents?

A) All NSAIDs (non-steroidal anti-inflammatory drugs) are unsafe in AERD regardless of COX selectivity because the IgE-mediated mechanism confers cross-reactivity across the entire class; acetaminophen is also contraindicated at any dose because it shares the aspirin antigenic epitope
B) Celecoxib (a COX-2-selective inhibitor) is generally safe at standard doses in AERD because it spares COX-1-mediated PGE2 synthesis; acetaminophen is generally safe at doses below 1 gram per dose because it has insufficient COX-1 inhibitory activity at this dose to trigger the PGE2 drop; all COX-1-inhibiting NSAIDs share cross-reactivity regardless of chemical structure
C) COX-1-inhibiting NSAIDs are unsafe in AERD only if they are chemically related to aspirin (salicylate structure); ibuprofen and naproxen (propionic acids) are safe because their different chemical class prevents the pharmacological COX-1 interaction that triggers leukotriene release
D) Acetaminophen at any dose is the preferred analgesic in AERD because it has no COX inhibitory activity whatsoever; celecoxib is contraindicated in AERD because its COX-2 selectivity causes compensatory upregulation of COX-1, worsening arachidonic acid shunting
E) Tramadol is the only analgesic safe for use in AERD patients because it does not interact with either the COX-1 or COX-2 pathway; all other analgesics including acetaminophen and celecoxib carry significant aspirin-exacerbation risk and should be avoided

ANSWER: B

Rationale:

In AERD, the mechanism of hypersensitivity is pharmacological (COX-1 inhibition reducing PGE2), not IgE-mediated or chemically structure-dependent. Therefore, all NSAIDs that inhibit COX-1 at anti-inflammatory doses share cross-reactivity, regardless of their chemical class — ibuprofen, naproxen, indomethacin, ketorolac, and diclofenac all trigger AERD reactions despite having different chemical structures from aspirin. COX-2-selective inhibitors such as celecoxib spare COX-1-mediated PGE2 synthesis at standard doses and are generally tolerated in AERD, though caution is warranted at higher doses because COX-2 inhibitors retain some residual COX-1 activity at high concentrations, particularly in patients with very severe AERD. Acetaminophen (paracetamol) at doses below 1 gram per dose is generally safe because it does not inhibit COX-1 sufficiently at this dose to trigger the PGE2 reduction that precipitates AERD reactions; however, at doses above 1 gram, some patients with severe AERD may react.

Option A: Option A is incorrect because AERD is not IgE-mediated; the mechanism is pharmacological COX-1 inhibition, not antigenic cross-reactivity; acetaminophen is generally safe at doses below 1 gram per dose (not contraindicated at any dose) because it lacks significant COX-1 inhibitory activity at these doses.
Option C: Option C is incorrect because the cross-reactivity in AERD is pharmacological (COX-1 inhibition), not chemical-structure-based; ibuprofen and naproxen are COX-1 inhibitors and are decidedly not safe in AERD — they are among the most common triggers of AERD reactions.
Option D: Option D is incorrect because acetaminophen does have some COX inhibitory activity and is not safe at all doses in AERD; at doses above 1 gram per dose it can trigger reactions in some severely affected patients; the claim that celecoxib upregulates COX-1 is pharmacologically inaccurate.
Option E: Option E is incorrect because celecoxib is generally safe in AERD (not contraindicated), and acetaminophen at doses below 1 gram is also generally safe; tramadol has no unique safety advantage in AERD over these agents, and the characterization of universal NSAID-class cross-reactivity excluding only tramadol is incorrect.

22. A 48-year-old woman with AERD (aspirin-exacerbated respiratory disease), severe nasal polyposis requiring two prior sinus surgeries, and ischemic heart disease requiring antiplatelet therapy is referred to a specialist center for aspirin desensitization. Which of the following correctly describes the procedure, its proposed mechanism, and the critical requirement for maintaining the tolerant state after desensitization?

A) Aspirin desensitization is performed by administering a single full therapeutic dose of aspirin (325 mg) in a monitored setting; if the patient tolerates this dose without reaction, the desensitization is complete and the patient may subsequently use aspirin and other NSAIDs without restriction and without any maintenance regimen
B) Aspirin desensitization involves parenteral administration of aspirin lysinate intravenously over 4–6 hours, titrating the infusion rate based on continuous bronchospasm monitoring; it achieves tolerance by permanently downregulating IgE receptor expression on mast cell surfaces, requiring no maintenance therapy
C) Aspirin desensitization is contraindicated in patients with ischemic heart disease because the aspirin doses required to achieve tolerance (typically exceeding 1 gram) produce irreversible platelet inhibition that substantially increases bleeding risk beyond what is acceptable for a patient with coronary artery disease
D) Aspirin desensitization involves supervised graded oral aspirin challenge starting at very low doses (typically 30–60 mg) with incremental dose increases over 1–3 days until tolerance to full-dose aspirin is achieved; proposed mechanisms include CysLT1 receptor downregulation and EP2 receptor upregulation; the tolerant state reverses within days of aspirin discontinuation and must be maintained with continuous daily aspirin use
E) Aspirin desensitization produces tolerance through induction of IL-10 (interleukin-10)-secreting regulatory T cells that suppress eosinophilic airway inflammation; once tolerance is established it is permanent and does not require maintenance aspirin; the procedure is performed in outpatient clinic without resuscitation equipment since reactions during low-dose challenge are uniformly mild

ANSWER: D

Rationale:

Aspirin desensitization is a specialized procedure available at centers experienced in managing AERD, indicated for patients who require aspirin for a medical indication (such as ischemic heart disease) or as a disease-modifying intervention in selected patients with severe refractory nasal polyposis. The procedure involves supervised graded oral aspirin challenge starting at very low doses (typically 30–60 mg) in a controlled inpatient or specialized outpatient setting with resuscitation equipment available, with incremental dose increases over 1–3 days until tolerance to full-dose aspirin (typically 325–650 mg twice daily) is achieved. The proposed mechanisms include downregulation of CysLT1 receptors, desensitization of mast cell and eosinophil responsiveness to CysLT1 signaling, and possible upregulation of the anti-inflammatory EP2 prostaglandin receptor. The critical clinical point is that the tolerant state is not permanent: it reverses within days of aspirin discontinuation. Therefore, maintaining desensitization requires continuous daily aspirin use without interruption; any gap in dosing requires repeat desensitization.

Option A: Option A is incorrect because desensitization is not achieved with a single full dose; it requires graded dose escalation starting at very low doses over 1–3 days; a single 325 mg challenge in a naive AERD patient would likely trigger a severe reaction, not establish tolerance; and maintenance therapy is mandatory.
Option B: Option B is incorrect because aspirin desensitization is performed by the oral route (graded oral challenge), not by IV infusion of aspirin lysinate; the mechanism does not involve IgE receptor downregulation — AERD is not IgE-mediated; and maintenance therapy is required.
Option C: Option C is incorrect because aspirin desensitization is not contraindicated in ischemic heart disease; in fact, the need for antiplatelet therapy in a patient with concurrent ischemic heart disease is one of the most compelling clinical indications for performing aspirin desensitization in an AERD patient; the doses required after successful desensitization (standard aspirin 325 mg twice daily) are standard antiplatelet doses, not supratherapeutic ones.
Option E: Option E is incorrect because the tolerant state achieved by aspirin desensitization is not permanent — it reverses within days of discontinuation and requires continuous daily aspirin maintenance; furthermore, aspirin challenges can produce severe bronchospasm requiring resuscitation, so the procedure must be performed in a setting with appropriate emergency equipment available.